ArticleInternational urology and nephrology2026
Validation of BIAS and IBCG criteria for predicting high-grade recurrence in low-grade NMIBC eligible for active surveillance.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the performance of two scoring systems-the Bladder Cancer Italian Active Surveillance (BIAS) criteria and the International Bladder Cancer Group (IBCG) score-for predicting high-grade (HG) disease at recurrence in patients with primary low-grade (LG) non-muscle-invasive bladder cancer eligible for active surveillance (AS).
methodsWe retrospectively included patients with primary LG-NMIBC (2013-2022), eligible for AS according to BIAS criteria at time of diagnosis. All subsequent recurrences were managed with TURBT, allowing histopathological confirmation of tumor grade across 383 recurrences. Clinical data necessary to assess IBCG criteria and adherence to BIAS protocol were systematically collected at each recurrence, and their diagnostic performance in predicting HG progression was evaluated using C-statistics. Multivariable logistic regression was used to assess which individual BIAS and IBCG criteria were most predictive of progression.
resultsAt a median (IQR) follow-up of 55 (18-83) months, HG progression occurred in 45/383 (12%) of recurrences. BIAS criteria were met in 59% (226/383) of recurrences, of which 5.3% showed upgrading to HG. Conversely, only 16% (62/383) of recurrences had 0 IBCG risk factors, of which 8 (13%) upgraded. BIAS showed higher discriminative ability than IBCG (C-statistics 0.68 vs. 0.47, p<0.001) and higher negative predictive value (95% vs. 87%).
conclusionIn patients with primary LG-NMIBC initially eligible for AS, adherence to BIAS criteria at recurrence identifies a subgroup with a lower prevalence of HG disease at immediate TURBT and may help inform shared decision-making regarding surveillance versus immediate intervention.
Indexed as
Identifiers
42834313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.